Biosciences Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle, UK.
Department of Applied Sciences, Northumbria University, Newcastle, UK.
Oncogene. 2021 Aug;40(33):5213-5223. doi: 10.1038/s41388-021-01923-1. Epub 2021 Jul 6.
The identification of cancer-specific vulnerability genes is one of the most promising approaches for developing more effective and less toxic cancer treatments. Cancer genomes exhibit thousands of changes in DNA methylation and gene expression, with the vast majority likely to be passenger changes. We hypothesised that, through integration of genome-wide DNA methylation/expression data, we could exploit this inherent variability to identify cancer subtype-specific vulnerability genes that would represent novel therapeutic targets that could allow cancer-specific cell killing. We developed a bioinformatics pipeline integrating genome-wide DNA methylation/gene expression data to identify candidate subtype-specific vulnerability partner genes for the genetic drivers of individual genetic/molecular subtypes. Using acute lymphoblastic leukaemia as an initial model, 21 candidate subtype-specific vulnerability genes were identified across the five common genetic subtypes, with at least one per subtype. To confirm the approach was applicable across cancer types, we also assessed medulloblastoma, identifying 15 candidate subtype-specific vulnerability genes across three of four established subtypes. Almost all identified genes had not previously been implicated in these diseases. Functional analysis of seven candidate subtype-specific vulnerability genes across the two tumour types confirmed that siRNA-mediated knockdown induced significant inhibition of proliferation/induction of apoptosis, which was specific to the cancer subtype in which the gene was predicted to be specifically lethal. Thus, we present a novel approach that integrates genome-wide DNA methylation/expression data to identify cancer subtype-specific vulnerability genes as novel therapeutic targets. We demonstrate this approach is applicable to multiple cancer types and identifies true functional subtype-specific vulnerability genes with high efficiency.
鉴定癌症特异性易损基因是开发更有效、毒性更低的癌症治疗方法的最有前途的方法之一。癌症基因组显示出数千种 DNA 甲基化和基因表达的变化,其中绝大多数可能是乘客变化。我们假设,通过整合全基因组 DNA 甲基化/表达数据,我们可以利用这种固有变异性来识别癌症亚型特异性易损基因,这些基因将代表新的治疗靶点,可以允许针对特定癌症的细胞杀伤。我们开发了一种生物信息学管道,整合全基因组 DNA 甲基化/基因表达数据,以鉴定个体遗传/分子亚型的遗传驱动因素的候选亚型特异性易损伙伴基因。我们使用急性淋巴细胞白血病作为初始模型,在五个常见的遗传亚型中鉴定出 21 个候选的亚型特异性易损基因,每个亚型至少有一个。为了确认该方法适用于多种癌症类型,我们还评估了髓母细胞瘤,在四个已建立的亚型中的三个中鉴定出 15 个候选的亚型特异性易损基因。几乎所有鉴定出的基因以前都没有与这些疾病有关。在两种肿瘤类型中对七个候选的亚型特异性易损基因的功能分析证实,siRNA 介导的敲低诱导了明显的增殖抑制/凋亡诱导,这与基因被预测为特异性致死的癌症亚型特异性相关。因此,我们提出了一种新的方法,该方法整合全基因组 DNA 甲基化/表达数据来鉴定癌症亚型特异性易损基因作为新的治疗靶点。我们证明该方法适用于多种癌症类型,并以高效率鉴定真正的功能亚型特异性易损基因。